Clinical Trials As a NCI-designated Comprehensive Cancer Center and a lead site for the National Clinical Trials Network, we provide national leadership in developing clinical trials, which offer more options for patients. With more than 300 open therapeutic trials available, we enroll nearly 1,000 patients each year. For a full listing, visit Spotlight: Genitourinary (GU) Cancers • A Phase I/II Trial of Enzalutamide Plus the Gluco- corticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC), IRB 13-0979 • A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymp- tomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Tes- tosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance), IRB 15-0956 • A Phase III, Open-Label, Multicenter, Random- ized Study of MPDL3280A (Anti-PD-L1 Antibody) vs. Observation as Adjuvant Therapy in Patients With PD-L1 Selected, High-Risk Muscle Invasive Bladder Cancer After Cystectomy, IRB 15-0630 • A Phase III, Multicenter, Randomized, Placebo- Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrec- tomy, IRB 16-1354 American Society of Clinical Oncology (ASCO) Annual Meeting JUNE 2–6, 2017 McCormick Place, 2301 S. King Dr., Chicago, IL Come visit us at Booth 4028 in the exhibition hall. See a full list of our faculty presentations at ASCO2017.pdf Follow the action on Twitter at @UCCancerCenter and #ASCO2017 Upcoming Events 2–6 JUNE Opening Night Cocktail Reception at the 2017 ASCO Annual Meeting FRIDAY, JUNE 2, 2017 The Signature Room at the 95th® Located atop the John Hancock Center 875 N. Michigan Ave, Chicago, IL RSVP at ASCOReception2017 2 JUNE Research CANCER.UCHICAGO.EDU 9